Moleculin Biotech, Inc. (MBRX): Nasdaq/NYSE listing notice — Moleculin Biotech receives Nasdaq extension to April 29, 2024 to meet $1 bid price rule

Moleculin Biotech, Inc.

Initial 180-day compliance period expired Nov 1, 2023; second period granted until April 29, 2024.
Company must close at $1.00+ for 10 consecutive business days to regain compliance.
If using reverse stock split, it must be completed by April 19, 2024 (10 business days before deadline).
Failure by April 29 may lead to delisting; company can appeal to Nasdaq Hearings Panel.
No immediate effect on trading; shares continue on Nasdaq under symbol MBRX.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Moleculin Biotech, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 2, 2023, the Company received an extension of the 180 calendar days from Nasdaq to regain compliance with the Bid Price Requirement, following the expiration of the initial 180 calendar days period to regain compliance. According to the notification from Nasdaq, the determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Bid Price Requirement, and the Company’s written notice of its intention to cure the defi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-030228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.